Status: Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.
Participants needed: 90
Trial details
Phase: Phase 3Age: 4-18Biological sex: MaleType: InterventionalSponsor: Dyne TherapeuticsUpdated: May 27, 2026Locations: 1
Eligibility criteria
Ambulatory male with confirmed diagnosis of DMD and with a mutation in the dystr... [+2]
Receipt of ongoing immunosuppressive therapy (other than glucocorticoids) within... [+6]